ReviewCancers2017
Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer.
Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- The importance microRNAs as a biomarker in lung cancer.Acta bio-medica : Atenei Parmensis · 2023Pooled it
- Prognostic Role of MicroRNAs in Human Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Disease markers · 2018Pooled it
- A meta-analysis: microRNAs' prognostic function in patients with nonsmall cell lung cancer.Cancer medicine · 2017Pooled it
- Multidimensional analysis of hsa-miR-140-3p and CKS1B correlation via the MAPK/ERK pathway in lung adenocarcinoma progression.Discover oncology · 2025Article
- Construction of a New Immune-Related Competing Endogenous RNA Network with Prognostic Value in Lung Adenocarcinoma.Molecular biotechnology · 2024Article
- Circ_0004140 promotes lung adenocarcinoma progression by upregulating NOVA2 via sponging miR-330-5p.Thoracic cancer · 2023Article
- Article
- Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.BMC cancer · 2022Article
- The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer.Molecular therapy oncolytics · 2022Article
- circ_0000567/miR-421/Journal of Cancer · 2022Article
- Lung cancer screening: who pays? Who receives? The European perspectives.Translational lung cancer research · 2021Review
- Circulating miR-320a Acts as a Tumor Suppressor and Prognostic Factor in Non-small Cell Lung Cancer.Frontiers in oncology · 2021Article
- MicroRNA profiling in BEAS-2B cells exposed to alpha radiation reveals potential biomarkers for malignant cellular transformation.Toxicology research · 2020Article
- Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer.Cancer science · 2020Article
- Clinical value of exhaled breath condensate let-7 in non-small cell lung cancer.International journal of clinical and experimental pathology · 2020Article
- The targeting of non‑coding RNAs by curcumin: Facts and hopes for cancer therapy (Review).Oncology reports · 2019Review
- miR-150-5p represses TP53 tumor suppressor gene to promote proliferation of colon adenocarcinoma.Scientific reports · 2019Article
- Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498.Journal of cellular and molecular medicine · 2019Article
- Evaluation of Plasma Extracellular Vesicle MicroRNA Signatures for Lung Adenocarcinoma and Granuloma With Monte-Carlo Feature Selection Method.Frontiers in genetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of deaths resulting from cancer owing to late diagnosis and limited treatment intervention. MicroRNAs are short, non-coding RNA molecules that regulate gene expression post-transcriptionally by translational repression or target messenger RNA degradation. Accumulating evidence suggests various roles for microRNAs, including development and progression of lung cancers. Because microRNAs are degraded to a much lesser extent in formalin-fixed paraffin-embedded specimens and are present not only in tumor tissues but also in body fluids, there is an increased potential in microRNA analyses for cancer research. In this review, recent studies of microRNA are introduced and briefly summarized, with a focus on the association of microRNAs with histological subtypes, genetic driver alterations, therapeutically-targeted molecules, and carcinogens. The reported circulating microRNA signature for the early detection of lung cancer and the implications of microRNAs as the modulators of tumor immune response are also introduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.